A new analysis found that prescriptions for Ozempic and similar drugs quadrupled in less than three years, with many patients using the diabetes drug to lose weight.
Health-care providers wrote more than 9 million prescriptions for Ozempic and similar drugs in the final three months of 2022, according to a new analysis of medications that have become highly sought-after for their weight-loss effects.The report, released Wednesday by data-analytics firm Trilliant Health, shows that quarterly prescriptions quadrupled between early 2020 and the end of last year.
The figure for total prescriptions is based on insurance claims and is likely an undercount. Many health plansdata for about 300 million Americans and examines health trends broadly, also found that a little more than half of patients taking Ozempic or a similar drug have a history of diabetes. That reinforces what has been widely assumed: Many patients are using diabetes drugs off-label for weight loss, according to Sanjula Jain, Trilliant’s chief research officer.
The analysis not the first to confirm the rise of the drugs, led by Ozempic, that have rapidly permeated popular culture and fueled a frenzy among patients and on Wall Street. A peer-reviewedlast year found that spending on semaglutide — the main ingredient in Ozempic and its weight-loss twin, Wegovy — was the fourth-highest among drugs nationally in 2021, increasing faster than for any other drug in the top 25. Both drugs are made by Danish drugmaker Novo Nordisk.
The new medications, often called GLP-1 drugs for the naturally occurring hormone they mimic, work by slowing the stomach from emptying and sending a signal of fullness to the brain. They have been found to help overweight people lose 15 to 20 percent of their body weight and reduce the
Canada Latest News, Canada Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
As amoxicillin shortage continues, prescriptions have plummeted, study finds: ‘Immediate, sweeping effect’Amid the ongoing amoxicillin shortage, a new study by physicians from Boston Children’s Hospital determined that the odds of a child being prescribed the medication for ear infections has plummeted.
Read more »
Ozempic and Other Weight-Loss Drugs Have Pummeled This Stock. It May Be a Buy.RBC Capital Markets analyst Nik Modi initiated coverage of Utz stock with an Outperform rating and $17 price target.
Read more »
Watch out, Ozempic? Another diabetes drug is 'superior' for weight loss in studiesType 2 diabetes treatment tirzepatide, which is sold under the brand name Mounjaro, awaits FDA approval as a weight-loss medication.
Read more »
What’s the Difference Between Mounjaro Vs. Ozempic? Experts ExplainDoctors break it down.
Read more »
“A Daily Nightmare:” One Year into the ADHD Stimulant ShortageOne year into the ADHD stimulant shortage, patients still struggle to fill their prescriptions for Adderall XR and other stimulants like Vyvanse, Concerta, and Focalin. Amid increased demand this back-to-school season, children and adults with ADHD are feeling exhausted by the persistent treatment strain.
Read more »
Missouri sues clinic that challenged ban on gender-transition drugs for minorsMissouri Attorney General Andrew Bailey has taken action against a clinic that sought to block the state’s ban on gender-transition drugs for minors, accusing the provider of previously treating children without adequate psychological evaluations.
Read more »